The patient was initially implanted with an afx2 bifurcated stent graft and an afx vela infrarenal to treat an abdominal aortic aneurysm (aaa).Approximately four (4) years subsequent to the initial procedure, the patient underwent a re-intervention due to implant movement, characterized by a decrease in overlap length.The attending physician opted to proceed with an afx vela infrarenal implantation.The final patient status was reported as being in stable condition.
|
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good-faith efforts to retrieve a reported adverse event/incident-related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.The review confirms there were no manufacturing or processing non-conformities identified that would contribute to the reported adverse event/incident.The device was not returned to endologix for evaluation.A clinical evaluation of the event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the overlap length became shorter and the additional endovascular procedure are confirmed.This is consistent with the reported event/incident.The most likely causation for the reported event is user related.It was noted that the insertion technique/process was off-label as the device ifu indicates the overlap between afx2 main body and extension should be 30-40mm; however, an overlap of only 20mm was reported as achieved.In addition, there was off-label concomitant use with non-endologix products outside the ifu.Procedure-related harms of this complaint could not be determined with the medical records available for review.The final patient status was reported to be stable.No additional investigation of this reported event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar events/incidents.Device iteration is afx2.
|